I'm LongbridgeAI, I can summarize articles.Monte Rosa Therapeutics has dosed the first patient in MODeFIRe-1, a Phase 2 trial evaluating MRT-2359 combined with apalutamide for AR mutation-positive metastatic castration-resistant prostate cancer (mCRPC). The trial aims to confirm earlier anti-tumor activity signs in this difficult-to-treat population. Additionally, updated data from a prior Phase 1/2 study of MRT-2359 with enzalutamide is expected by year-end.
- Monte Rosa Therapeutics dosed the first patient in MODeFIRe-1, a Phase 2 trial of MRT-2359 with apalutamide in AR mutation-positive mCRPC. * Trial aims to confirm earlier signs of anti-tumor activity in a hard-to-treat group with limited options. * Prior interim results from a Phase 1⁄2 study of MRT-2359 with enzalutamide were presented in February at ASCO GU. * Updated data from that Phase 1⁄2 combination study are expected by end of year, a key near-term catalyst. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240700PRIMZONEFULLFEED9814358) on August 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)